See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Pope Francis
Donald Trump
Vladimir Putin
Elon Musk
Immigration
CPAC
Basketball
Vatican
Wrestling
Baseball
MLS
Tennis
Published • loading... • Updated

Roche Shares Promising Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease

Summary by EuropaWire.eu
Roche Shares Promising Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease (IN BRIEF) Roche has announced results from the Phase IIb PADOVA study evaluating prasinezumab in 586 individuals with early-stage Parkinson’s disease. While the primary endpoint of time to confirmed motor progression narrowly missed statistical significance, promising efficacy trends were observed, particularly among participants receiving …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

6 Articles

All
Left
Center
Right
neurologylive.comneurologylive.com

Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes

Although the primary goal was not met, prasinezumab demonstrated encouraging effects on secondary and exploratory measures, such as time to worsening motor function, Clinical Global Impression of Change, MDS-UPDRS motor scores.

Read Full Article
EuropaWire.euEuropaWire.eu

Roche Shares Promising Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease

Roche Shares Promising Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease (IN BRIEF) Roche has announced results from the Phase IIb PADOVA study evaluating prasinezumab in 586 individuals with early-stage Parkinson’s disease. While the primary endpoint of time to confirmed motor progression narrowly missed statistical significance, promising efficacy trends were observed, particularly among participants receiving …

Read Full Article
Parkinson's News TodayParkinson's News Today

Prasinezumab slows motor progression, misses main trial goal

Treatment with investigational antibody therapy prasinezumab tended to slow the progression of motor symptoms in people with early-stage Parkinson’s disease in a Phase 2b trial, with particularly pronounced benefits among those also receiving levodopa. However, the difference between prasinezumab and a placebo in the overall study population didn’t reach statistical significance — meaning it’s not certain that the outcome is not due to chance — …

Read Full Article
hassteveclarkresignedyet.cahassteveclarkresignedyet.ca

Roche Phase IIb study of prasinezumab did not measure primary endpoint, but suggests possible benefit in early-stage Parkinson’s | 12/19/24 – hassteveclarkresignedyet

PADOVA showed numerical delayed motor progression and positive trends for several secondary and exploratory endpoints Prazinezumab continues to be well tolerated and no new safety features have been observed Roche continues to evaluate the data and will work with public health authorities to determine next steps Basel, December 19, 2024. – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the Phase IIb PADOVA study, which investi…

Read Full Article
contractpharma.comcontractpharma.com

Roche's Parkinson's Disease Drug Misses Primary Endpoint

Prasinezumab continues to be well tolerated and no new safety signals were observed.

Read Full Article
biopharma-reporter.combiopharma-reporter.com

Roche and Prothena’s Parkinson’s antibody treatment fails at phase 2

The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better for treating some subgroups than others.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharma-reporter.com broke the news in on Thursday, December 19, 2024.
Sources are mostly out of (0)

Similar News Topics

Parkinson's Disease

Parkinson's Disease

News
For You
Search
BlindspotLocal